Physician profile
Andrew S Mccraw
NPI 1992762611
$1,063.45
in general payments reported to CMS, 2019-2025
17 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.23 · 2020: $112 · 2021: $393 · 2022: $187 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $168.11 | 2025 | Filmarray Torch Module |
| Zimmer Biomet Holdings, INC. | $148.08 | 2025 | |
| Abbvie INC. | $114.77 | 2021-2025 | |
| Amgen INC. | $94.02 | 2019-2022 | |
| Amarin Pharma, INC. | $86.78 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $83.08 | 2020-2022 | |
| Esperion Therapeutics, INC. | $67.31 | 2020-2022 | |
| Dexcom, INC. | $55.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.14 | 2021-2022 | |
| Novo Nordisk INC | $44.25 | 2019-2021 | |
| Abbott Laboratories | $44.20 | 2021-2022 | |
| Pfizer INC. | $27.48 | 2021 | |
| Glaxosmithkline, LLC. | $18.52 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.25 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.86 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.05 | 2021 | |
| Daiichi Sankyo INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mccraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.